What specific drugs are included in the new pricing rules?

The new pricing rules issued by the National Pharmaceutical Pricing Authority (NPPA) apply Trade Margin Rationalisation (TMR) to 137 non-scheduled anti-cancer drugs.

While the complete list of 137 formulations was recommended by an Expert Committee under the Directorate General of Health Services (DGHS), the official release explicitly highlights the following key drugs and therapeutic classes:

Live Test Series

Join thousands of aspirants in our weekly live mock tests. Get real-time ranking and detailed analysis.

Join Now

Specifically Identified Drugs & Classes

Immunotherapy Therapies: Capped for treatments covering over 20 types of cancers, specifically citing widely used drugs such as Pembrolizumab and Durvalumab.

Osimertinib: A widely prescribed advanced anti-cancer drug.

Denosumab: Used primarily by breast cancer and prostate cancer patients.

Pegfilgrastim: Used to prevent neutropenia (severe low white blood cell count) during chemotherapy.

Live NCERT Foundation

Master the basics with our live NCERT classes. The perfect foundation for your UPSC journey.

Start Learning

Bevacizumab: An approved therapy for treating colon, ovarian, and cervical cancers.

Rule Highlights & Timelines

Trade Margin Cap: Capped at 30% of the Maximum Retail Price (MRP) under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013.

Price Impact: Lowering trade margins is expected to reduce MRPs by up to 70%.

Implementation: The revised prices take effect on 9 November 2026. Manufacturers must submit revised prices within 7 days, and hospitals/pharmacies are mandated to display updated price lists.

Advanced GS Course

Deep dive into General Studies with our comprehensive expert-led modules.

View Details